Greene S A
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman 99164-6610, USA.
Clin Tech Small Anim Pract. 1999 Feb;14(1):10-4. doi: 10.1016/s1096-2867(99)80022-x.
The alpha-2 agonists have been used in veterinary practice for over 30 years following the introduction of xylazine (ROMPUN, Bayer Corp., Shawnee Mission, KS) in 1962. The decision to use alpha-2 agonists in anesthesia practice should be based on factors including patient disposition, presenting complaint, type of procedure, and the veterinarian's familiarity with the drug. Controversy surrounds the issue of using anticholinergic agents concurrent with the alpha-2 agonists. Patient selection and procedure type can aid in determining when use of an anticholinergic with the alpha-2 agonist is advantageous. Antagonism of alpha-2 agonists can be readily accomplished. Commonly, alpha-2 agonists are used in combination with other agents to provide neuroleptanalgesia or sedation prior to general anesthesia.
自1962年赛拉嗪（隆朋，拜耳公司，堪萨斯州肖尼使命）问世以来，α2激动剂已在兽医临床应用了30多年。在麻醉实践中使用α2激动剂的决定应基于包括患者性情、就诊主诉、手术类型以及兽医对该药物的熟悉程度等因素。围绕α2激动剂与抗胆碱能药物同时使用的问题存在争议。患者选择和手术类型有助于确定何时将抗胆碱能药物与α2激动剂联合使用是有利的。α2激动剂的拮抗作用很容易实现。通常，α2激动剂与其他药物联合使用，以在全身麻醉前提供神经安定镇痛或镇静作用。
